相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing
David C. Turner et al.
CLINICAL CANCER RESEARCH (2014)
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts
Maurizio Rocchetti et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Miroslav Dostalek et al.
CLINICAL PHARMACOKINETICS (2013)
Role of bevacizumab in colorectal cancer growth and its adverse effects: A review
Efstathios T. Pavlidis et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos et al.
ANGIOGENESIS (2012)
The Relationship between Drug Clearance and Body Size Systematic Review and Meta-Analysis of the Literature Published from 2000 to 2007
Sarah C. McLeay et al.
CLINICAL PHARMACOKINETICS (2012)
Theoretical Considerations of Target-Mediated Drug Disposition Models: Simplifications and Approximations
Peiming Ma
PHARMACEUTICAL RESEARCH (2012)
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Martin Bergstrand et al.
AAPS JOURNAL (2011)
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2011)
Gene Expression of Vascular Endothelial Growth Factor A, Thymidylate Synthase, and Tissue Inhibitor of Metalloproteinase 3 in Prediction of Response to Bevacizumab Treatment in Colorectal Cancer Patients
Toshiaki Watanabe et al.
DISEASES OF THE COLON & RECTUM (2011)
Increase of Plasma VEGF after Intravenous Administration of Bevacizumab Is Predicted by a Pharmacokinetic Model
Marianne O. Stefanini et al.
CANCER RESEARCH (2010)
Target-mediated drug disposition model for drugs that bind to more than one target
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2010)
An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics
David Ternant et al.
THERAPEUTIC DRUG MONITORING (2010)
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
Radojka M. Savic et al.
AAPS JOURNAL (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics
Leonid Gibiansky et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer
Jong Gwang Kim et al.
CLINICAL CANCER RESEARCH (2008)
Approximations of the target-mediated drug disposition model and identifiability of model parameters
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade
John S. Rudge et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Platelets take up the monoclonal antibody bevacizumab
Henk M. W. Verheu et al.
CLINICAL CANCER RESEARCH (2007)
Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF)
AM Byrne et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2005)
PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2005)
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma
F De Vita et al.
CANCER (2004)
Complexation of VEGF with bevacizumab decreases VEGF clearance in rats
V Hsei et al.
PHARMACEUTICAL RESEARCH (2002)
Assessment of actual significance levels for covariate effects in NONMEM
U Wählby et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
分享论文
